Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Amicus Therapeutics

Evaluate

Thumbnail
July 28, 2023

Go or no go? Biogen and Astellas head towards key Pdufas

Thumbnail
June 30, 2023

Go or no go? Decision day looms for Eisai and Biogen

Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.

Article image
Vantage logo
May 01, 2023

Sanofi pumps up its Pompe portfolio with Maze deal

In licensing Maze’s oral contender, the group has made another bet against gene therapies.

Article image
Vantage logo
December 22, 2022

Go or no go? Lecanemab’s destiny approaches

2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.

Article image
Vantage logo
December 01, 2022

US FDA approval tracker: November 2022

Article image
Vantage logo
November 01, 2022

US FDA approval tracker: October 2022

Article image
Vantage logo
October 12, 2022

ESGCT 2022 – Sangamo strengthens its case in Fabry

The group looks like the gene therapy contender to beat, but that is not saying much.

Article image
Vantage logo
September 29, 2022

Go or no go? GSK takes its turn with a novel anaemia class

Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.

Article image
Vantage logo
September 01, 2022

US FDA approval tracker: August 2022

Article image
Vantage logo
July 28, 2022

Go or no go? J&J’s bispecific FDA first

Pdufa decisions also beckon for Amicus, Acadia and Bluebird.

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May 2022

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up